Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes

February 8, 2024 updated by: Chungnam National University Hospital

The objective of this observational study is to provide basic data for predicting and analyzing the occurrence and causes of delayed cognitive impairment, an important factor in the quality of life, among discharged patients who have received targeted temperature management therapy and experienced favorable neurological outcomes after out-of-hospital cardiac arrest.

The main questions it aims to answer are:

  • Can we identify abnormal areas in the brains of patients with delayed cognitive impairment using Brain MRI or positron emission tomography (PET) imaging?
  • Is it possible to predict delayed cognitive impairment using biomarkers?

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

  1. For study subjects who survived after out-of-hospital cardiac arrest, prognosis was evaluated using Cerebral Performance Category (CPC) scores on days 10-14 after return of spontaneous circulation (ROSC). A CPC score of 1-2 indicates a good neurological prognosis, while a score of 3-5 indicates a poor neurological prognosis. Only subjects with CPC scores of 1-2 were included in this study.

  2. Blood samples were collected through venous puncture at days 10-14, 3 months, and 6 months after ROSC, and the obtained blood was drawn into an serum separating tube (SST) bottle without anticoagulants, then centrifuged within 60 minutes after collection (at 3,000rpm for at least 10 minutes) and divided into tubes. The processed tubes were stored at -70°C.

    • The storage period of the samples is 5 years from the date of collection, and they are stored in a coded manner for anonymization.
    • The Human Neurology 4-ples A 2.0 Assay Kit (including neurofilament light chain, Tau protein, ubiquitin carboxyl terminal esterase L1 protein [UCHL1], and glial fibrillary acidic protein antibody) was analyzed using the single molecule protein detection (SIMOA) analysis machine, and neuron-specific enolase (NSE) in the blood was analyzed together as a reference point to assess the usefulness of each biomarker.
  3. Through the Seoul Neuropsychological Screening Battery (SNSB), attention, language and related functions, visuospatial function, memory, frontal lobe and executive function, and other related functions can be assessed. The test is conducted by a specialist clinical psychologist for 1 hour and 30 minutes to 2 hours, and the results are analyzed by Professor Oh Eung-Seok, a neurologist. The presence of cognitive impairment is assessed by conducting tests at 10-14 days, 3 months, and 6 months after ROSC for out-of-hospital cardiac arrest patients with CPC 1-2 points who have passed 10-14 days since ROSC. In addition, through detailed item analysis of the SNSB, functional abnormalities and affected areas (such as the frontal lobe, parietal lobe, temporal lobe, and occipital lobe) are analyzed.
  4. We consulted with the departments of radiology, nuclear medicine, and neurology professors to establish the optimal fluorine-18 (18F) fluorodeoxyglucose (FDG) PET & MRI examination protocol. The first MRI examination was performed 72-96 hours after ROSC, as recommended by international treatment guidelines for predicting neurological prognosis. The first [18F]-FDG PET examination was performed at 10-14 days after ROSC, as it may result in false positives if performed too early in cardiac arrest patients. A minimum of 10 days is recommended before performing the examination. If cognitive impairment is observed in the SNSB examination at 3 months after ROSC, a second [18F]-FDG PET & MRI examination is performed. If the cognitive function is normal at 6 months, the examination is performed regardless of cognitive impairment.
  5. Prediction and analysis of delayed cognitive impairment and cause analysis in out-of-hospital cardiac arrest patients with good neurological outcomes
  6. Delayed cognitive impairment is defined based on the SNSB results, and is defined as the positive group. For biomarkers, differences between the positive and negative groups are determined at each time point, and the predictive power and cut-off values are determined using area under the receiver operating characteristics curve. For images, the functional or anatomical differences between the two groups are compared.
  7. Predictive power analysis Through SNSB, the patient's cognitive impairment and the time point of recognition are measured, and the level of biomarkers tested prior to the recognition of impairment is checked to analyze the predictive power. Therefore, the time points for predictive power analysis are 10-14 days, 3 months, and 6 months after ROSC. The first and second [18F]-FDG PET & MRI findings are analyzed to identify differences between the cognitive impairment group and the normal group. Using multiple modes combining clinical data, biomarkers, [18F]-FDG PET, MRI, etc., a predictive model for delayed cognitive impairment is developed.
  8. Cause analysis Investigate the impairment findings and location using the continuously measured SNSB test values. Analyze the first and second [18F]-FDG PET and MRI findings to investigate the functional or anatomical abnormalities occurring in patients with cognitive impairment.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

For subjects who survived after out-of-hospital cardiac arrest, the prognosis was evaluated 10-14 days after ROSC using CPC. For CPC 1-2, neurological prognosis was evaluated as good, and for CPC 3-5, neurological prognosis was evaluated as poor. Only cases of CPC 1-2 between 10 and 14 days after ROSC were included in this study.

Description

Inclusion Criteria:

  • Patients who visited the hospital emergency room due to cardiac arrest within 60 months after Institutional Review Board (IRB) approval
  • Patients with Glasgow Coma Scale (GCS) less than 8 points after spontaneous circulation recovery
  • Patients who are 18 years old or older
  • Patients who underwent targeted temperature management (TTM)
  • Patients who showed good neurological outcomes with CPC 1-2 points after evaluating the prognosis on days 10-14 after ROSC

Exclusion Criteria:

  • Under 18 years of age
  • cardiac arrest cause is trauma
  • Patients who have not undergone targeted temperature management
  • Patients treated with extracorporeal membrane oxygenation (ECMO)
  • Patients who were not able to undergo SNSB testing
  • Patients who could not be followed up until 6 months after ROSC

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Good neurological outcome
Patients who showed good neurological outcomes with CPC scores of 1-2 at discharge
Other: nothing
Follow-up observation was conducted without any intervention in an outpatient setting.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cognitive impairment
Time Frame: at 10-14 days, 3 months, and 6 months after return of spontaneous circulation
Through the Seoul Neuropsychological Screening Battery (SNSB), attention, language and related functions, visuospatial function, memory, frontal lobe and executive function, and other related functions can be assessed. The test is conducted by a specialist clinical psychologist for 1 hour and 30 minutes to 2 hours, and the results are analyzed by Professor Oh Eung-Seok, a neurologist.
at 10-14 days, 3 months, and 6 months after return of spontaneous circulation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chungnam National University Hospital

Investigators

  • Study Chair: Jung Soo Park, MD.Phd, (35015) Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2023

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

March 29, 2023

First Submitted That Met QC Criteria

April 24, 2023

First Posted (Actual)

April 26, 2023

Study Record Updates

Last Update Posted (Estimated)

February 9, 2024

Last Update Submitted That Met QC Criteria

February 8, 2024

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CNUH 2022-10-059-004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There are no plans to make individual participant data (IPD) available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Impairment

Clinical Trials on nothing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe